Synthesis and transdermal permeation of novel N4- methoxypoly(ethylene glycol) carbamates of cytarabine

Drug Development and Industrial Pharmacy

Volumn 36, Issue 12, 2010, Pages 1477-1485

  Legoabe, Lesetja J ^a   N'Da, David D ^a   Breytenbach, Jaco C ^a   Du Preez, Jan L ^a   Du Plessis, Jeanetta ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Carbamate; Cytarabine; Derivatives; Log D; Methoxypoly(ethylene glycol); Percutaneous absorption; Physicochemical properties; Skin penetration; Transdermal delivery systems

Indexed keywords

CARBAMIC ACID DERIVATIVE; CYTARABINE; CYTARABINE N4 METHOXYDIETHYLENEOXYCARBAMATE; CYTARABINE N4 METHOXYDODECAETHYLENEOXYCARBAMATE; CYTARABINE N4 METHOXYETHYLENEOXYCARBAMATE; CYTARABINE N4 METHOXYHEPTADECAETHYLENEOXYCARBAMATE; CYTARABINE N4 METHOXYOCTAETHYLENEOXYCARBAMATE; CYTARABINE N4 METHOXYTRIETHYLENEOXYCARBAMATE; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; DRUG SOLUBILITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN TISSUE; HYDROPHILICITY; LIPID SOLUBILITY; LIPOPHILICITY; SKIN PERMEABILITY;

ADMINISTRATION, CUTANEOUS; ANTIMETABOLITES, ANTINEOPLASTIC; CARBAMATES; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTARABINE; FEMALE; HUMANS; MASS SPECTROMETRY; PERMEABILITY; POLYETHYLENE GLYCOLS; SKIN; SKIN ABSORPTION; SOLUBILITY;

EID: 78149390560     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.488646     Document Type: Article

References (42)

1. Galmarini C, Mackey J, Dumontet C. (2002). Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol, 3(7):415.
2. Hadfield AF, Sartorelli AC. (1984). The pharmacology of prodrugs of 5-fluorouracil and 1-?-D-arabinofuranosylcytosine. Adv Pharmacol Chemother, 20:21-67.
3. Hamada A, Kawaguchi T, Nakano M. (2002). Clinical pharmacokinetics of cytarabine formulations. Clin Pharmacokinet, 41(10):705-18.
4. Rustum YM, Raymakers RA. (1992). 1-β-arabinofuranosylcytosine in therapy of leukemia: Preclinical and clinical overview. Pharmacol Ther, 56(3):307-21.
5. Bolwell BJ, Cassileth PA, Gale RP. (1988). High dose cytarabine: A review. Leukemia, 2(5):253-60.
6. Frei E, Bickers JN, Hewlett JS, Lane M, Leary WV, Talley RW. (1969). Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878). Cancer Res, 29(7):1325-32.
7. Boyer SH, Erion MD. (2004). Novel cytarabine monophosphate prodrugs. US application number 10/698928; Publication Date: 05/13/2004; Filing Date: 10/31/2003; International Classes: (IPC1-7): C07H019/10; C07H019/048; A61K031/7072; http://www.freepatentsonline.com/y2004/0092476.html [accessed April 29, 2010].
8. Brachwitz H, Bergmann J, Fichtner I, Thomas Y, Vollgraf C, Langen P, et al. (1998). 1-β-D-arabinofuranosylcytosine-5'- alkylphosphonophosphates and diphosphates: New orally active derivatives of ara-C. J Lipid Res, 39(1):162-72.
9. Fadl TA, Hasegawa T, Youssef AF, Farag HH, Omar FA, Kawaguchi T. (1995). Synthesis and investigation of N4-substituted cytarabine derivatives as prodrugs. Pharmazie, 50(6):382-7.
10. Kluge M, Schott H. (1997). Cytarabine derivatives, the preparation and use thereof. US patent no. 5641758.
11. Wang N, Chen ZC, Lu DS, Lin XF. (2005). Controllable selective synthesis of a polymerizable prodrug of cytarabine by enzymatic and chemical methods. Bioorg Med Chem Lett, 15(18):4064-7.
12. Sloan KB. (1989). Prodrugs for dermal delivery. Adv Drug Deliv Rev, 3:67-101.
13. Sloan KB, Wasdo S. (2003). Designing for topical delivery: Prodrugs can make the difference. Med Res Rev, 23(6):763-93.
14. Sloan KB, Wasdo, SC. (2006). Topical delivery using prodrugs 2.1.2. In: Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley JW, eds. Prodrugs: Challenges and rewards, part 1. New York: Springer Science.
15. Naik A, Kalia YN, Guy RH. (2000). Transdermal drug delivery: Overcoming the skin's barrier function. Pharm Sci Technol Today, 3(9):318-26.
16. Honeywell-Nguyen PL, Bouwstra JA. (2005). Vesicles as a tool for transdermal and dermal delivery. Drug Discov Today Tech, 2(1):67-74.
17. du Plessis J, Pugh W, Judefeind A, Hadgraft J. (2002). Physicochemical determinants of dermal drug delivery: Effects of the number and substitution pattern of polar groups. Eur J Pharm Sci, 16(3):107.
18. Pugh WJ, Degim IT, Hadgraft J. (2000). Epidermal permeability- penetrant structure relationships: 4, QSAR of permeant diffusion across human stratum corneum in terms of molecular weight, H-bonding and electronic charge. Int J Pharm, 197(1-2):203-11.
19. Roberts MS, Pugh WJ, Hadgraft J, Watkinson AC. (1995). Epidermal permeability-penetrant structure relationships. Part 1. Analysis of methods of predicting penetration of monofunctional solutes from aqueous solutions. Int J Pharm, 126:219-33.
20. Silverman BR. (2004). Prodrugs and drug delivery systems. In: Silverman BR, ed. The organic chemistry of drug design and drug action. 2nd ed. San Diego: Elsevier Academic Press, 497-549.
21. Bonina FP, Puglia C, Barbuzzi T, de Caprariis P, Palagiano F, Rimoli MG, et al. (2001). In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. Eur J Pharm Sci, 14(2):123-34.
22. Puglia C, Filosa R, Peduto A, De Caprariis P, Rizza L, Bonina F, et al. (2006). Evaluation of alternative strategies to optimize ketorolac transdermal delivery. AAPS PharmSciTech, 7(3):E1-9.
23. Ballico M, Cogoi S, Drioli S, Bonora GM. (2003). Postsynthetic conjugation of biopolymers with high molecular mass poly(ethylene glycol): Optimization of a solution process tested on synthetic oligonucleotides. Bioconjug Chem, 14(5):1038-43.
24. Cleary GW. (1993). Biological factors in absorption and permeation. In: Zatz JL, ed. Skin permeation: Fundamentals and applications. Wheaton: Allured, 300.
25. Hadgraft J, Wolff M. (1993). Physicochemical and pharmacokinetic parameters affecting percutaneous absorption. In: Gurny R, Teuber A, eds. Dermal and transdermal drug delivery: New insights and perspectives: Second international symposium of the international association of pharmaceutical technology (APV), November 11-13, 1991. Frankfurt, Stuttgart: Wissenschaftliche Verlagsgesellschaft.
26. Jordan FL. (2008). In JRX Biotechnology, Inc. (Irvine, CA) (ed.), Mixture for transdermal delivery of low and high molecular weight compounds (424/489 ed.). US A61K 9/14 (20060101).
27. Li J, Zhai YL, Zhang B, Deng LD, Xu YS, Dong AJ. (2008). Methoxy poly(ethylene glycol)-block-poly(D,L-lactic acid) copolymer nanoparticles as carriers for transdermal drug delivery. Polym Int, 57(2):268-74.
28. Bodansky M. (1955). Synthesis of peptides by aminolysis of nitrophenyl esters. Nature, 175:685.
29. N'Da DD, Breytenbach JC. (2009). Synthesis of methoxypoly( ethylene glycol) carbonate prodrugs of AZT and penetration through human skin in vitro. J Pharm Pharmacol, 61:1-11.
30. Magnusson BM, Anissimov YG, Cross SE, Roberts MS. (2004). Molecular size as the main determinant of solute maximum flux across the skin. J Investig Dermatol, 122:993-9.
31. Gerber M, Breytenbach JC, du Plessis J. (2008). Transdermal penetration of zalcitabine, lamivudine and synthesised N-acyl lamivudine esters. Int J Pharm, 351(1):186-93.
32. Kiptoo PK, Paudel KS, Hammell DC, Hamad MO, Crooks PA, Stinchcomb AL. (2008). In vivo evaluation of a transdermal codrug of 6-b-naltrexol linked to hydroxybupropion in hairless guinea pigs. Eur J Pharm Sci, 33(4-5):371-9.
33. Taylor HE, Sloan KB. (1998). 1-alkylcarbonyloxymethyl prodrugs of 5-fluorouracil (5-FU): Synthesis, physicochemical properties, and topical delivery of 5-FU. J Pharm Sci, 87(1):15-20.
34. Bonate P, Howard D. (2004). Pharmacokinetics in drug development: Regulatory and developmental paradigms, vol. 2, Arlington: AAPS Press.
35. Kligman AM, Christophers E. (1963). Preparation of isolated sheets of human stratum corneum. Arch Dermatol, 88:702-5.
36. Steyn AGW, Smit CF, Du Toit SHC, Strasheim C. (1996). Modern statistics in practice. 2nd ed. Pretoria: J.L. van Schaik.
37. StatSoft Inc. (2007). STATISTICA (data analysis software system). Tulsa, OK.
38. Guy RH, Hadgraft J. (1992). Percutaneous penetration enhancement: Physicochemical considerations and implications for prodrug design. In: Sloan KB, ed. Prodrugs: Topical and ocular drug delivery. New York: Marcel Dekker, 1-16.
39. Solomons TWG. (1995). Organic chemistry. 6 ed. New York: John Wiley & Sons.
40. Bonina FP, Montenegro L, De Caprariis P, Palagiano F, Trapani G, Liso G. (1995). In vitro and in vivo evaluation of polyoxyethylene indomethacin esters as dermal prodrugs. J Control Release, 34(3):223-32.
41. Goldsmith LA. (1991). In: Goldsmith LA, ed. Physiology, biochemistry and molecular biology of the skin. 2nd ed. New York: Oxford University Press.
42. Bieze TWN, Barnes AC, Huige CJM, Enderby JE, Leyte JC. (1994). Distribution of water around poly(ethylene oxide): A neutron diffraction study. J Phys Chem, 743:49-52.